Literature DB >> 9378496

Selective enhancement of endothelial cell VCAM-1 expression by interleukin-10 in the presence of activated leucocytes.

C Fiehn1, E M Paleolog, M Feldmann.   

Abstract

Although initially described as an immunomodulatory cytokine, interleukin-10 (IL-10) has also been proposed to exert proinflammatory effects both in vivo and in vitro. In particular, studies in IL-10 transgenic mice have suggested that IL-10 may activate vascular endothelium to promote leucocyte adhesion and extravasation. In the present study we investigated whether IL-10 activates endothelial cells either directly or indirectly, via signals produced by leucocytes in the endothelial cell environment, using a co-culture of human umbilical vein endothelial cells and peripheral blood mononuclear cells (PBMC). No direct effects of IL-10 on endothelial cell responses were observed. However, in the presence of phytohaemagglutinin-activated PBMC, IL-10 increased the expression on endothelial cells of vascular cell adhesion molecule-1 (VCAM-1) but not of intercellular adhesion molecule-1, E-selectin or major histocompatibility complex (MHC) antigens, an effect mediated by PBMC-derived soluble factors. We also observed that interferon-gamma (IFN-gamma) antagonized VCAM-1 expression on endothelial cells mediated by IL-4 and IL-13. Since IL-10 has previously been documented to down-regulate release of IFN-gamma by PBMC, we propose that the IL-10-mediated reduction of IFN-gamma production by PBMC results in enhanced responsiveness of endothelial cells to PBMC-derived IL-4 and IL-13, and thus increased expression of VCAM-1. Our results suggest that the relative balance of cytokines produced by infiltrating cells in developing inflammatory lesions may differentially modulate endothelial responsiveness in vivo, and that IL-10 might indirectly stabilize VCAM-1 expression on endothelial cells by affecting the balance of leucocyte-derived cytokines in the endothelial environment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378496      PMCID: PMC1363877          DOI: 10.1046/j.1365-2567.1997.00286.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain.

Authors:  R L Palmer-Crocker; C C Hughes; J S Pober
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  TGF-beta 1, IL-10 and IL-4 differentially modulate the cytokine-induced expression of IL-6 and IL-8 in human endothelial cells.

Authors:  C C Chen; A M Manning
Journal:  Cytokine       Date:  1996-01       Impact factor: 3.861

3.  Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms.

Authors:  M H Thornhill; S M Wellicome; D L Mahiouz; J S Lanchbury; U Kyan-Aung; D O Haskard
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

4.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

5.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

Authors:  F Rousset; E Garcia; T Defrance; C Péronne; N Vezzio; D H Hsu; R Kastelein; K W Moore; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

6.  The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.

Authors:  R A Seder; W E Paul; M M Davis; B Fazekas de St Groth
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

7.  IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor.

Authors:  P Ralph; I Nakoinz; A Sampson-Johannes; S Fong; D Lowe; H Y Min; L Lin
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

8.  Interleukin-10 induces E-selectin on small and large blood vessel endothelial cells.

Authors:  M Vora; L I Romero; M A Karasek
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

9.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.

Authors:  R de Waal Malefyt; J Abrams; B Bennett; C G Figdor; J E de Vries
Journal:  J Exp Med       Date:  1991-11-01       Impact factor: 14.307

View more
  3 in total

1.  Adhesion between human neutrophils and immobilized endothelial ligand vascular cell adhesion molecule 1: divalent ion effects.

Authors:  Elena B Lomakina; Richard E Waugh
Journal:  Biophys J       Date:  2009-01       Impact factor: 4.033

2.  Interleukin-4 and interleukin-10 are chondroprotective and decrease mononuclear cell recruitment in human rheumatoid synovium in vivo.

Authors:  C Jorgensen; F Apparailly; I Couret; F Canovas; C Jacquet; J Sany
Journal:  Immunology       Date:  1998-04       Impact factor: 7.397

3.  Nitric oxide expression by interleukin-10 in the endoscopic and open methods of vein harvesting in coronary artery bypass surgery.

Authors:  Sadir Alrawi; Farkad Balaya; Ramanathan Raju; Djamshid Shirazian; Anthony Acinapura; Joseph Cunningham
Journal:  JSLS       Date:  2002 Jan-Mar       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.